Cancer Family
Genitourinary System Neoplasm
CI-CAN-00000018Explore in graph →
Non-malignant3,849 active trials61 approved drugs306 evidence items
- NCIt
- C156482
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000018Explore in graph →
Clinical trials
17,388 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07702721 | Intraoperative Microscopic Assessment of Lymph Node Status in Gynecological Malignancies(IMAGINE) | not yet recruiting | — | 160 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 0 | Jul 14, 2026 | clinicaltrials |
| NCT07702864 | Pilot Feasibility Study of a Dyadic Culinary Nutrition Intervention(CHEF) | not yet recruiting | N/A | 40 | University of ArizonaOTHER |
| 1 |
| Jul 14, 2026 |
| clinicaltrials |
| NCT07699640 | Minimally-invasive ICG-guided Retroperitoneal Sentinel Lymph Node Dissection in the Primary Staging of Testicular Cancer Versus Standard of Care(RAISN 2) | not yet recruiting | N/A | 171 | Heinrich-Heine University, DuesseldorfOTHER | 2 | Jul 13, 2026 | clinicaltrials |
| NCT07637851 | Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer(RegeNovar) | not yet recruiting | Phase 1 / Phase 2 | 43 | ARCAGY/ GINECO GROUPOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07696169 | Disease Evolution and Risk Factors of AIDS-related Prevalent Cancers | not yet recruiting | — | 1,000 | Shenzhen Third People's HospitalOTHER | 0 | Jul 10, 2026 | clinicaltrials |
| NCT07669363 | Hexaminolevulinate Photodynamic Therapy (HAL-PDT) With Deferred Surgery Versus Surgery for High-grade Squamous Intraepithelial Lesions (HSIL)(Aurora) | not yet recruiting | Phase 2 | 230 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT07692919 | VIA Versus Colposcopy | not yet recruiting | — | 200 | Sohag UniversityOTHER | 0 | Jul 9, 2026 | clinicaltrials |
| NCT07693894 | DISARM Clinical Study B: Evaluation of Innovative Ovarian Cancer Biomarker Assays(DISARM CSB) | not yet recruiting | — | 2,080 | National and Kapodistrian University of AthensOTHER | 0 | Jul 9, 2026 | clinicaltrials |
| NCT07689240 | Testing the Investigational Medication Pembrolizumab After Kidney Removal for Patients With Non-Clear Cell Renal Cell Carcinoma | not yet recruiting | Phase 3 | 400 | National Cancer Institute (NCI)NIH | 0 | Jul 8, 2026 | clinicaltrials |
| NCT07690462 | Infrared Fluorescence Staining Versus Frozen Section for Prostate Cancer Surgery | not yet recruiting | — | 120 | Xiangya Hospital of Central South UniversityOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07690878 | PTC-guided Neoadjuvant Therapy For Muscle-invasive Bladder Cancer | not yet recruiting | Phase 2 | 35 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07686744 | Neoantigen Peptide Vaccine Plus Pembrolizumab in Renal Cell Carcinoma(NPVPP) | not yet recruiting | Phase 1 | 8 | Jian LinOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT07682584 | Predictors of BCR After RARP for Localized Prostate Cancer: A Retrospective Analysis | not yet recruiting | — | 200 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 0 | Jul 6, 2026 | clinicaltrials |
| NCT07682649 | Escalating Cycle 1 Dose of Lu-177-PSMA-617 for the Treatment of Metastatic Castration Resistant Prostate Cancer(ESCENDO) | not yet recruiting | Phase 1 | 20 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07683013 | Safety, Tolerability, and Efficacy of CP-PCA07 in Combination With Enzalutamide in Patients With Castration-Resistant Prostate Cancer | not yet recruiting | Phase 1 | 18 | Hyundai Bioscience Co., Ltd.INDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07671937 | INtegrating Systematic PatIent-Reported Evaluations in Multi-Disciplinary Tumor Boards: The INSPIRE Study(INSPIRE) | not yet recruiting | N/A | 2,748 | University of Alabama at BirminghamOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07655557 | Sexual Health Communication Skills Training Intervention for Patients With Prostate Cancer | not yet recruiting | N/A | 100 | NYU Langone HealthOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07677566 | 177Lu-PSMA-617 Combined With Darolutamide in Neoadjuvant Treatment of High-risk Localized Prostate Cancer: a Prospective, Single-arm, Multi-center Clinical Trial(IUNU-PC-123) | not yet recruiting | Phase 4 | 20 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07674615 | IMMU-132 in TROP-2 Overexpressed Advanced and Relapsed Ovarian Cancer | not yet recruiting | Phase 1 | 19 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07675733 | A Study of Short-course Hypofractionated Online-adaptive Radiotherapy for the Post-operative Treatment of Endometrial Cancer: Tolerability and Feasibility(SHORTEN) | not yet recruiting | N/A | 30 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07545460 | A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer | not yet recruiting | Phase 3 | 404 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07574489 | Whole Versus Partial Gland Boost During Prostate SBRT | not yet recruiting | Phase 2 / Phase 3 | 186 | University of NebraskaOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07672782 | Tisotumab Vedotin in Squamous Cell Carcinoma of the Vulva | not yet recruiting | Phase 2 | 28 | GOG FoundationNETWORK | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07673211 | Circulating cfDNA and HPV as Prognostic Biomarkers for First-Line Recurrent Metastatic Cervical Cancer | not yet recruiting | — | 60 | Zhejiang Cancer HospitalOTHER | 0 | Jun 29, 2026 | clinicaltrials |
| NCT07673835 | Iparomlimab and Tuvonralimab Plus Chemotherapy as Neoadjuvant Therapy for Ovarian Cancer（Phase II） | not yet recruiting | Phase 2 | 49 | Obstetrics & Gynecology Hospital of Fudan UniversityOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07674121 | PROLONG (PRostateOLaparibONcombinationGcc) Study(PROLONG) | not yet recruiting | — | 75 | AstraZenecaINDUSTRY | 0 | Jun 29, 2026 | clinicaltrials |
| NCT07670962 | Blood-Based Minimal Residual Disease in Advanced Epithelial Ovarian Cancer After 1st Line Therapy | not yet recruiting | — | 300 | Asan Medical CenterOTHER | 0 | Jun 26, 2026 | clinicaltrials |
| NCT07652073 | A Study of DAT-2645 in Patients With BRCA1/2 Mutations or HRD-Positive Ovarian Cancer | not yet recruiting | Phase 2 | 30 | Danatlas Pharmaceuticals Co., LtdINDUSTRY | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07663747 | Enfortumab Vedotin + Pembrolizumab Induction to Spare the Bladder in MIBC(FIDELIO) | not yet recruiting | Phase 2 | 56 | The Netherlands Cancer InstituteOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07668284 | COQ10 and Vitamin E for Off-Target Radiation Toxicity | not yet recruiting | Phase 1 / Phase 2 | 200 | University of NebraskaOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07529080 | Personalized Cancer Support (Thrive Track) to Manage the Emotional Needs of Young Adults With Thyroid, Melanoma and Testicular Cancer, PerCS-YA Trial | not yet recruiting | N/A | 142 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07664397 | Imaging Study of [89Zr]DFO-YS5 for Cancer Detection | not yet recruiting | Phase 1 | 40 | Robert Flavell, MD, PhDOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07664735 | A Phase 1 Study to Evaluate the Safety and Efficacy of OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer. | not yet recruiting | Phase 1 | 30 | Outpace Bio, Inc.INDUSTRY | 0 | Jun 24, 2026 | clinicaltrials |
| NCT07664956 | Cyclobenzaprine for Postoperative Pain in Minimally Invasive Hysterectomy | not yet recruiting | Phase 4 | 36 | Christiana Care Health ServicesOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07665684 | Samuraciclib in Combination With Gemcitabine/Nab-Paclitaxel in Patients With Metastatic Basal-Like Pancreatic Cancer(SONIC) | not yet recruiting | Phase 1 / Phase 2 | 67 | University Health Network, TorontoOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT06770855 | Consolidative Metastasis and Primary Directed Therapy (MPDT) for Renal Cell Carcinoma (RCC) | not yet recruiting | N/A | 23 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT07662863 | Sacituzumab Tirumotecan vs MMAE-ADCs in Advanced Urothelial Carcinoma (FUSCC-SPARE-UC-01)(SPARE-UC-01) | not yet recruiting | Phase 2 | 75 | Fudan UniversityOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT07663006 | Breast and Cervical Cancer Stigma in Rwanda | not yet recruiting | N/A | 1,116 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT07663513 | Iparomlimab and Tovorilimab (QL1706) Combined With Bevacizumab and Chemotherapy as Neoadjuvant Therapy for Advanced Ovarian Cancer | not yet recruiting | Phase 2 | 36 | Fudan UniversityOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT07478536 | Stockholm3 Test Validation in Men on Active Surveillance in Switzerland (CHAS3 Trial)(CHAS3) | not yet recruiting | — | 350 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT07656337 | Effects of Direct Artery Injection on Prostate Cancer Drug Delivery and Tumor Uptake: Imaging-Based Prediction of Treatment Effectiveness(IAPSMA) | not yet recruiting | N/A | 10 | Lithuanian University of Health SciencesOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07339384 | Signatera Assessment in Early-Stage Endometrial Cancer(SIGNAL-EMC 101) | not yet recruiting | N/A | 1,010 | Natera, Inc.INDUSTRY | 1 | Jun 17, 2026 | clinicaltrials |
| NCT07644910 | Nudging Preventive Screening Via Message Framing and Bundling | not yet recruiting | N/A | 235,000 | University of ChileOTHER | 0 | Jun 17, 2026 | clinicaltrials |
| NCT07652515 | A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Primary Advanced or Recurrent Endometrial Cancer | not yet recruiting | Phase 4 | 100 | GlaxoSmithKlineINDUSTRY | 0 | Jun 17, 2026 | clinicaltrials |
| NCT07649174 | Cadonilimab Plus Chemotherapy in LACC: A Prospective, Multicenter, Randomized Phase II Trial | not yet recruiting | Phase 2 | 134 | Obstetrics & Gynecology Hospital of Fudan UniversityOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07635108 | MR-guided Single-fraction SBRT for Nodal Oligorecurrent Prostate Cancer (PINPOINT)(PINPOINT) | not yet recruiting | N/A | 48 | Odense University HospitalOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT07647653 | Fluzoparib + Bevacizumab vs Olaparib + Bevacizumab for Maintenance Therapy in HRD-Positive Advanced Ovarian Cancer | not yet recruiting | Phase 2 | 120 | Shandong UniversityOTHER | 0 | Jun 15, 2026 | clinicaltrials |
| NCT07642531 | A Modular Cloud Platform For Fertility Preservation | not yet recruiting | N/A | 140 | Biruni UniversityOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07644754 | Patients With Metastasized Prostate Cancer Whose Prostate-specific Antigen-level (PSA) Remains >0,2 ng/ml After Six Months of Dual Antihormonal Therapy Will Receive Radiotherapy to the Prostate and Radiotherapy to Refractory Metastases(RIALTO) | not yet recruiting | N/A | 27 | University Hospital TuebingenOTHER | 0 | Jun 12, 2026 | clinicaltrials |
| NCT07645716 | Evaluation of Interactions and Group Processes in Multidisciplinary Tumor Boards in Gynecologic Oncology(GOLD) | not yet recruiting | — | 400 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Jun 12, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 14, 2026source: clinicaltrials